Inhibiting the Growth of 3D Brain Cancer Models with Bio-Coronated Liposomal Temozolomide
Authors:
- Giordano PeriniGPGiordano Perini
- Francesca GiulimondiFGFrancesca Giulimondi
- Valentina PalmieriValentina Palmieri
- Alberto AugelloAAAlberto Augello
- Luca DigiacomoLDLuca Digiacomo
- Erica QuagliariniEQErica Quagliarini
- Daniela PozziDPDaniela Pozzi
- Massimiliano PapiMassimiliano Papi
- Giulio CaraccioloGiulio Caracciolo
Open Access
- 12 March 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (3) , 378
Abstract
Nanoparticles (NPs) have emerged as an effective means to deliver anticancer drugs into the brain. Among various forms of NPs, liposomal temozolomide (TMZ) is the drug-of-choice for the treatment and management of brain tumours, but its therapeutic benefit is suboptimal. Although many possible reasons may account for the compromised therapeutic efficacy, the inefficient tumour penetration of liposomal TMZ can be a vital obstacle. Recently, the protein corona, i.e., the layer of plasma proteins that surround NPs after exposure to human plasma, has emerged as an endogenous trigger that mostly controls their anticancer efficacy. Exposition of particular biomolecules from the corona referred to as protein corona fingerprints (PCFs) may facilitate interactions with specific receptors of target cells, thus, promoting efficient internalization. In this work, we have synthesized a set of four TMZ-encapsulating nanomedicines made of four cationic liposome (CL) formulations with systematic changes in lipid composition and physical−chemical properties. We have demonstrated that precoating liposomal TMZ with a protein corona made of human plasma proteins can increase drug penetration in a 3D brain cancer model derived from U87 human glioblastoma multiforme cell line leading to marked inhibition of tumour growth. On the other side, by fine-tuning corona composition we have also provided experimental evidence of a non-unique effect of the corona on the tumour growth for all the complexes investigated, thus, clarifying that certain PCFs (i.e., APO-B and APO-E) enable favoured interactions with specific receptors of brain cancer cells. Reported results open new perspectives into the development of corona-coated liposomal drugs with enhanced tumour penetration and antitumour efficacy.Keywords
This publication has 61 references indexed in Scilit:
- Convection-enhanced delivery of nanodiamond drug delivery platforms for intracranial tumor treatmentNanomedicine: Nanotechnology, Biology and Medicine, 2014
- Glioblastoma Multiforme Therapy and Mechanisms of ResistancePharmaceuticals, 2013
- Multicellular Tumor Spheroids for Evaluation of Cytotoxicity and Tumor Growth Inhibitory Effects of Nanomedicines In Vitro: A Comparison of Docetaxel-Loaded Block Copolymer Micelles and Taxotere®PLOS ONE, 2013
- Blood–brain barrier structure and function and the challenges for CNS drug deliveryJournal of Inherited Metabolic Disease, 2013
- 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testingBMC Cancer, 2013
- Transferrin-appended PEGylated nanoparticles for temozolomide delivery to brain:in vitrocharacterisationJournal of Microencapsulation, 2010
- Efficient Escape from Endosomes Determines the Superior Efficiency of Multicomponent LipoplexesThe Journal of Physical Chemistry B, 2009
- Enhanced Transfection Efficiency of Multicomponent Lipoplexes in the Regime of Optimal Membrane Charge DensityThe Journal of Physical Chemistry B, 2008
- High Level of Low‐density Lipoprotein Receptors Enhance Hypericin Uptake by U‐87 MG Cells in the Presence of LDLPhotochemistry and Photobiology, 2007
- Experimental combination chemotherapy of ACNU and 5‐FU against cultured glioma model (spheroid) and subcutaneous rat gliomaInternational Journal of Cancer, 1987